|
|
| | GR 83895 Basic information |
| Product Name: | GR 83895 | | Synonyms: | GR 83895;L-Phenylalanine, N2-[(6-aminohexahydro-5-oxo-5H-thiazolo[3,2-a]pyridin-3-yl)carbonyl]-L-arginylglycyl-L-α-aspartyl-, cyclic (4→1)-peptide, [3S-(3α,6β,8aα)]- (9CI) | | CAS: | 152323-73-4 | | MF: | C29H39N9O8S | | MW: | 673.74046 | | EINECS: | | | Product Categories: | | | Mol File: | 152323-73-4.mol |  |
| | GR 83895 Chemical Properties |
| density | 1+-.0.1 g/cm3(Predicted) | | pka | 4.00±0.10(Predicted) |
| | GR 83895 Usage And Synthesis |
| Description | GR 83895 is a prototype fibrinogen receptor antagonist. | | Uses | GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM)[1]. | | References | [1] Foster MR, et al. Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs. Thromb Res. 1993 Nov 1;72(3):231-45. DOI:10.1016/0049-3848(93)90190-y |
| | GR 83895 Preparation Products And Raw materials |
|